Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-718 in Huntington's disease
NCT03787758Phase 1Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Feb 2019
- Primary completion
- Oct 2019
- Modality
- Allosteric Modulators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalzanemdor in Huntington's disease (HD), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoints: Adverse Events at 21 days, Vital Signs at 21 days and 3 more. Started Feb 2019; status: completed.
02
Drugs
dalzanemdor
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT03787758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787758.